Clinical Context
Many patients with type 2 diabetes eventually require insulin therapy as beta-cell function declines. Basal insulin effectively controls fasting glucose but often inadequately addresses postprandial excursions and provides no assistance with weight management—in fact, insulin therapy typically promotes weight gain. For patients on basal insulin who remain above HbA1c targets, intensification options include adding prandial insulin (with associated weight gain and hypoglycemia risk) or adding GLP-1 RAs.
The combination of basal insulin with GLP-1 RAs is mechanistically complementary: basal insulin controls overnight hepatic glucose output, while GLP-1 RAs enhance meal-time insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. This combination addresses both fasting and postprandial hyperglycemia through distinct mechanisms.
SUSTAIN 5 tested whether adding semaglutide to established basal insulin therapy provides additional glycemic benefit without the weight gain and increased hypoglycemia that would accompany prandial insulin intensification. This trial positioned semaglutide as an alternative intensification strategy for insulin-treated patients.
PICO Summary
Population: Adults with type 2 diabetes (n=397), HbA1c 7.0-10.0%, on stable basal insulin (± metformin) therapy.
Intervention: Once-weekly subcutaneous semaglutide at 0.5 mg or 1.0 mg for 30 weeks, added to existing basal insulin.
Comparison: Volume-matched placebo weekly, with continued basal insulin.
Outcome: Semaglutide 0.5 mg reduced HbA1c by 1.4% and 1.0 mg by 1.8%, compared to 0.1% with placebo. Body weight decreased by 3.7 kg (0.5 mg) and 6.4 kg (1.0 mg) versus 1.4 kg increase with placebo. More semaglutide patients achieved HbA1c <7.0% (61-67% vs 13%). Hypoglycemia rates were similar across groups. Gastrointestinal adverse events were more common with semaglutide.
Clinical Pearls
1. Substantial Additional Efficacy Beyond Basal Insulin: The 1.8% HbA1c reduction with semaglutide 1.0 mg on top of basal insulin is remarkable—demonstrating that significant glycemic improvement is achievable even in patients already on insulin. This exceeds what prandial insulin typically adds and comes with weight loss rather than weight gain.
2. Weight Loss Despite Insulin Background: While placebo patients on basal insulin gained 1.4 kg, semaglutide patients lost up to 6.4 kg. This 7.8 kg weight differential is clinically meaningful and addresses one of the most frustrating aspects of insulin therapy for patients and clinicians alike.
3. No Increased Hypoglycemia: A critical concern when adding glucose-lowering therapy to insulin is hypoglycemia risk. Reassuringly, semaglutide didn’t increase hypoglycemia despite substantially lowering HbA1c. This reflects GLP-1 RA’s glucose-dependent mechanism—enhanced insulin secretion only when glucose is elevated.
4. High Target Achievement: While only 13% of placebo patients achieved HbA1c <7.0%, this increased to 61-67% with semaglutide. For patients stuck above target despite basal insulin optimization, adding semaglutide substantially increases the probability of reaching glycemic goals.
Practical Application
For patients on basal insulin (± metformin) who remain above HbA1c target, adding semaglutide offers an attractive alternative to prandial insulin intensification. Consider this approach particularly when: patients are concerned about weight gain, hypoglycemia risk needs to be minimized, once-weekly dosing is preferred over multiple daily injections, or patients are unwilling to add prandial insulin complexity.
When initiating combination therapy, maintain basal insulin at current dose initially. As semaglutide is titrated and glucose improves, basal insulin dose may need reduction to avoid hypoglycemia. Monitor fasting glucose and adjust insulin accordingly. Some patients may be able to reduce or discontinue basal insulin altogether as semaglutide effect accrues.
The combination of basal insulin + GLP-1 RA is now available as a fixed-ratio combination product (insulin degludec/liraglutide as Xultophy; insulin glargine/lixisenatide as Soliqua). These simplify administration but offer less dose flexibility than separate products.
Broader Evidence Context
SUSTAIN 5 confirms findings from other GLP-1 RA + basal insulin combination trials. Guidelines now recommend this combination as an alternative to basal-bolus insulin intensification, particularly for patients prioritizing weight management or hypoglycemia avoidance. The combination leverages complementary mechanisms for comprehensive glucose control.
The LixiLan and DUAL programs established this combination approach with other GLP-1 RAs. Semaglutide’s superior efficacy within the GLP-1 RA class suggests it may be the preferred GLP-1 RA partner for basal insulin.
Study Limitations
The 30-week duration doesn’t address long-term combination therapy durability. The trial permitted insulin dose adjustment but didn’t mandate titration to specific targets, potentially underestimating achievable glycemic control with optimized insulin dosing. The placebo comparison confirms semaglutide efficacy but doesn’t directly compare to prandial insulin intensification.
Bottom Line
Adding semaglutide to basal insulin produces substantial additional HbA1c reduction (up to 1.8%) and significant weight loss (up to 6.4 kg) without increasing hypoglycemia. For patients on basal insulin who remain above glycemic targets, semaglutide offers effective intensification that addresses postprandial glucose while avoiding the weight gain associated with prandial insulin addition.
Source: Rodbard HW, et al. “Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.” Journal of Clinical Endocrinology & Metabolism, 2018;103(6):2291-2301. Read article
